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Abstract Here we investigated how a coating of intravas-
cular balloon with paclitaxel (drug-coated balloon; DCB,
FreewayTM) impacted porcine peripheral artery vascular
function and remodeling. Domestic swine (n = 54) under-
went percutaneous overstretch balloon dilation of femoral
and iliac arteries, controlled by angiography and optical
coherence tomography (OCT). Paclitaxel tissue uptake was
measured at 1 h and 1, 3, and 9 days post-dilation. At these
time-points and at 32 ± 2 days, vascular function of the
dilated arteries was assessed using the organ chambermodel.
Neointimal growth and remodeling indices were determined
using OCT and histology at 32 ± 2 days. Intima and media
fibrosis were quantified by picrosirius red staining. Post-in-
flation femoral artery tissue drug levels were 460 ± 214,
136 ± 123, 14 ± 6, and 0.1 ± 0.1 ng/mg at 1 h and 1, 3,
and 9 days, respectively. Compared to plain balloon, Free-
wayTM resulted in a significantly smaller neointimal area
(P\ 0.05), less tunica intima (8.0 ± 5.4 vs 14.2 ± 4.7 %)
and media fibrosis (15.6 ± 7.7 vs 24.5 ± 5.4 %), and less
femoral artery constrictive remodeling (remodeling index:
1.08 ± 0.08 vs 0.94 ± 0.08). The DCB was associated with
significantly increased vasoconstrictor tone and endothe-
lium-dependent vasodilation impairment shortly after post-
overstretch injury. Overall, DCB dilation of peripheral
arteries resulted in high drug uptake into arterial tissue.
Compared with the plain balloon, the DCB was associated
with decreased vessel wall fibrosis after balloon overstretch
injury, and reduced degrees of constrictive remodeling and
neointimal hyperplasia.
1 Introduction
As treatment for atherosclerotic peripheral artery disease,
percutaneous transluminal angioplasty shows limited suc-
cess due to high restenosis rates [1–3], with 1-year patency
rates of 75–85 % after bare-metal stent (BMS) placement
[4–6]. Studies testing the implantation of drug-eluting stents
(DES) in the superficial femoral artery to prevent restenosis
have shown conflicting results, with DES showing advan-
tages over BMS in the short term (6 months) [3], but with
diminishing benefits over a longer time [6]. Sirolimus-coated
stents are more consistently superior for treating focal
infrapopliteal lesions when compared with BMS [7]. In the
Zilver PTX randomized study of patients with peripheral
artery disease, implantation of polymer-free DES led to
improved 12-month results compared to balloon dilation,
with similar superiority results when balloon dilation was
followed by provisional DES stenting [8].
The use of drug-coated balloons (DCBs) represents an
alternative approach to DES for local antiproliferative drug
delivery into the vessel wall [9–13]. DCB employment in
peripheral endovascular procedures has been successfully
demonstrated in pre-clinical [14–17] and clinical [18–24]
studies.
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Optical coherence tomography (OCT) has recently been
introduced into clinical practice to allow in vivo visual-
ization of stent strut coverage with neo-endothelium [25].
Correct imaging of femoral or iliac vessels is technically
challenging due to the large size of the peripheral arteries.
Accordingly, current publications describing OCT use in
peripheral arteries are limited to case reports [26, 27] and
ex vivo imaging [28].
We previously demonstrated that drug deposition in
coronary arteries leads to time-dependent impairment of
vascular function, despite decreased restenosis [29]. Unlike
in coronary arteries, the long atherosclerotic lesions of
human peripheral vessels can exhibit both adaptive and
constrictive remodeling within a single vessel [30], carrying
potential consequences of both vessel thrombotic occlusion
and severe restenosis. No systematic investigation has yet
reported how peripheral arterial wall remodeling is impacted
by percutaneous intervention with a paclitaxel-coated bal-
loon, and any related mechanical injury.
The present pre-clinical investigation aimed to assess
the vascular response to antiproliferative drug accumula-
tion in the peripheral arteries after balloon dilation with the
paclitaxel-coated balloon FreewayTM (Eurocor, Germany).
The impact was examined in terms of vessel remodeling
and vasodilatory or vasoconstrictive capacity of the
femoral or iliac arteries compared to with plain balloon
dilation.
2 Materials and methods
2.1 Local drug-delivery device
The FreewayTM balloon is a peripheral dilation balloon for
use in humans. Its surface is coated with 3.0 lg/mm2
paclitaxel using the shellac-coating technique. The bal-
loon’s tri-fold design protects the drug coating from early
wash-off into the peripheral circulation while the balloon is
introduced.
2.2 Experimental design
This study was approved by the Ethical Committee on
Animal Experiments at the University of Kaposvar, Hun-
gary. Our study protocol conformed to the ‘‘Position of the
American Heart Association on Research Animal Use,’’
adopted by the AHA on November 11, 1984.
The design of this prospective study is illustrated in
Fig. 1, and described in detail in the Supplementary
Materials and methods. Briefly, domestic pigs (weight
30–40 kg, n = 54) were pre-treated with 300 mg clopi-
dogrel and 250 mg acetylsalicylic acid. After overnight
fasting, the pigs were anesthetized for the peripheral
intervention. Into the right and left femoral and iliac
arteries (four vessels in each pig), we introduced the
FreewayTM or plain balloon (femoral: diameter of 5.0 or
6.0 mm and length of 20 mm; iliac: diameter of 7.0 or
8.0 mm and length of 40 mm). The balloons were then
inflated with 6–12 atm pressure to achieve a 1.3:1 balloon/
artery ratio, producing overstretch injury. Balloon inflation
was controlled by angiography, and the inflated balloon
size was related to the vessel size displayed by the baseline
angiography. The duration of balloon inflation was 60 or
120 s, depending on the experimental setup. The animals
were allowed to recover after the procedure. Upon com-
pleting the predetermined follow-up time, the animals were
humanely euthanized with saturated potassium chloride.
2.2.1 Pharmacokinetic study
Blood samples were taken at 5, 10, 20, and 60 min after the
interventional procedure. At 1 h and 1, 3, and 9 days of
follow-up, the paclitaxel concentration in femoral and iliac
arterial tissue was measured using high-performance liquid
chromatography (AnaKat Institut fu¨r Biotechnologie
GmbH, Berlin, Germany) [31, 32]. In five animals, the
proximal and distal reference segments of five iliac and
femoral arteries (2-min dilation groups) were dissected. All
balloon remnants were stored for measurements of pacli-
taxel on the surface.
2.2.2 Vascular response study measuring vasoconstrictor
tone and endothelium-dependent and -independent
vasodilation
Vasomotor reactions—including contraction, and endothe-
lium-dependent and -independent vasodilation—were mea-
sured using the organ chamber model, as previously
described [29] (Supplementary Materials and Methods).
2.2.3 Vascular remodeling study
Our investigation of vascular remodeling included OCT and
histology analyses. During a follow-up period of
32 ± 2 days, the pigs received a daily dose of 75 mg
clopidogrel and 100 mg acetylsalicylic acid. At the end of
the study, angiography and OCT imaging were performed,
and then the animals were euthanized. For histopathological
and histomorphometric analyses, the peripheral arterieswere
flushed with 100 mL saline, followed by pressure fixation in
4 % buffered formaldehyde at 100–110 mmHg for 30 min.
2.3 OCT imaging and analysis
For OCT imaging, a DragonflyTM catheter (St. Jude Med-
ical, Lightlab Imaging, Inc., Westford, MA) was placed
131 Page 2 of 15 J Mater Sci: Mater Med (2016) 27:131
123
3 cm distal to the affected peripheral artery segment, and
images were acquired via motorized pullback [25]. The
images were digitally stored using the ILUMIEN System
(St. Jude Medical, St. Paul, MN). The large artery size
prohibited blood clearance with a single contrast medium
flush. Thus, OCT image acquisition was combined with
proximal gentle balloon occlusion of the artery using low
balloon inflation pressure [26]. The analysis is described in
detail in the Supplementary Materials and Methods.
Briefly, for the lesion with the highest degree of stenosis,
we determined the remodeling index as the IEM area of the
lesion divided by the IEM area of the reference segment
(mean IEM of the proximal and distal reference segments
within 1 cm of the lesion edge) [25]. A remodeling index of
[1 or \1 was considered to indicate adaptive or con-
strictive remodeling, respectively.
2.4 Histopathology and histomorphometry
The formalin-fixed dilated segments were cut into distal,
mid, and proximal segments. These pieces were embedded
in paraffin, cut into 4– 6-lm-thick slices, and routinely
stained with hematoxylin–eosin and modified Movat’s
pentachrome and picrosirius staining. We used planimetry
to quantify fibrosis of the tunica intima, media, and
adventitia as described elsewhere [33]. All histopatholog-
ical, histomorphometric, and immunohistochemical analy-
ses were performed in accordance with published
guidelines by experienced investigators who were blinded
to the treatment (Supplementary Materials and Methods).
The remodeling index was calculated as the external elastic
lamina (EEL) area of the lesion with the highest grade of
stenosis divided by the EEL area of the reference segment
(mean value of the proximal and distal reference EEL
area).
2.5 Statistics
The continuous parameters of the angiographic, histologic,
and physiologic analyses are expressed as mean ± stan-
dard deviation. Tissue and plasma paclitaxel levels are
presented as mean ± standard error. The continuous
Fig. 1 Study design, including pharmacokinetic, vascular response (physiological), and vessel remodeling (with additional safety and efficacy)
investigations
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variables of the plain balloon and FreewayTM groups were
compared using the two-sided Student’s t test with a sig-
nificance level of 0.05. All measurements were performed
offline by an independent observer who was blinded to the
randomization group. For all OCT images, the lumen area
of the selected region of interest was repeatedly assessed
by one observer, as well as assessed by a second observer,
enabling calculation of the intra- and inter-observer vari-
ability of the OCT measurements. Statistical analyses were
performed using SPSS for Macintosh version 19.
3 Results
Figure 2 depicts the baseline anatomy of the porcine
superficial femoral and iliac arteries. The common iliac
artery was longer and wider than the femoral arteries,
having a size similar to human femoral arteries and thus
being better suited for testing human DCBs. The iliac
arteries are more elastic, with collagen and elastin fibers
dominating in the tunica media, and relatively few smooth
muscle fibers. In contrast, the femoral arteries are muscu-
lar-type arteries, showing predominant content of smooth
muscle cells.
Overstretch balloon dilation led to severe vessel injury
in each case, as confirmed by angiography, OCT, and
histology (Figs. 3, 4, 5). OCT images showed severe vessel
wall injury after overstretch balloon dilation, including
dissection, and parietal and intraluminal floating thrombi,
but without acute artery closure. At 1 h after balloon
dilation, fluorescent staining of the femoral arterial cross-
sections showed cell-rich (plain balloon) or cell-poor
(FreewayTM) intraluminal thrombus formation, and mas-
sive expression of tumor necrosis factor-alpha by the
inflammatory cells and platelets (Figs. 3, 4, 5).
3.1 Paclitaxel accumulation in the peripheral vessel
wall
Compared with 1-min dilation, the 2-min inflation time
was definitively more effective in terms of tissue retention
of the drug in both arteries (Figs. 6, 7). Therefore, we
used the 2-min balloon inflation time in our vascular
response and remodeling studies, which is also the more
commonly used inflation time in human peripheral
interventions.
Following 2-min balloon inflation of the femoral arter-
ies, the paclitaxel concentration at the 1-h follow-up was
36.9 ± 17.8 ng/mg in the proximal reference segments and
17.0 ± 6.3 ng/mg in the distal reference segments. As
expected, the plasma paclitaxel concentration decreased
with time after DCB use. At 5 and 10 min after a 1-min
balloon inflation, the paclitaxel concentrations decreased
from 9.2 ± 4.5 to 0 ng/mL. At 5, 10, 20, and 60 min after
a 2-min balloon inflation, the paclitaxel concentrations
were 14.6 ± 6.8, 10.2 ± 4.9, 7.7 ± 3.1, and 0.6 ± 0.4 ng/
mL, respectively. The percentages of paclitaxel remaining
on the balloon surface after the procedures were
53.2 ± 9.8 and 30.9 ± 4.3 % following 1- and 2-min
dilation of the femoral arteries, respectively.
Fig. 2 Angiography of the
femoral and iliac arteries before,
during, and after balloon
dilation. a Porcine superficial
femoral artery at baseline,
during balloon dilation, and
post-dilation. Severe post-




(arrow). b Porcine arteria iliaca
externa artery at baseline,
during balloon dilation, and
post-dilation. Acute vessel
dilation due to injury of the
adventitia following overstretch
injury (arrow)
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3.2 Vessel remodeling study
Quantitative peripheral angiography revealed that Free-
wayTM dilation was associated with a significant percent-
age of decrease in the stenosis diameter of the femoral
arteries, and with a trend toward less stenosis of the iliac
arteries (Tables 1, 2). Among ten selected OCT images, the
intra- and inter-observer variability values were r = 0.95
and r = 0.91 (P\ 0.001), respectively. At 32 ± 2 days,
OCT imaging revealed that FreewayTM was associated
with a significantly lower percentage area of stenosis in
both the femoral and iliac arteries (Tables 3, 4). With the
use of plain balloons, OCT indicated vessel constriction
(Figs. 4, 5). Quantitative OCT images revealed a remod-
eling index of\1 in femoral arteries dilated with a plain
balloon, suggesting constrictive remodeling (Tables 3, 4).
No meaningful arterial remodeling was observed in the
elastic-type iliac arteries (Tables 3, 4).
Histopathological analyses showed similar inflamma-
tion and injury scores between the two groups. Both
device groups showed complete endothelialization in
femoral arteries. In the iliac arteries, endothelialization
was complete in the plain balloon group and was
95 ± 5 % with the FreewayTM balloon (Tables 5, 6). No
vessel calcification was observed. Histomorphometric
analyses of both arteries revealed that the FreewayTM
group showed a significantly larger lumen area, smaller
neointimal area, and lower percentage area of stenosis
compared to these values in the plain balloon group
(Tables 7, 8). Alpha-actin staining revealed invasion of
smooth muscle cells into the intima in the femoral arteries
after plain balloon use, in contrast with the FreewayTM-
Fig. 3 OCT and histologic imaging of balloon overstretch injury of
the peripheral (femoral and iliac) arteries. A OCT imaging, showing
intima and media rupture (red arrow), vessel dissection (blue arrow),
and platelet-rich white thrombus (yellow arrow). B Histology,
showing (a) artery rupture with hemorrhage (black arrow) and
(b) severe intima and media injury (black arrow). Swine iliac arteries
at 1 h after balloon overstretch injury, shown with MOVAT staining
and under 94(a) and 98(b) magnification. C, D Tumor necrosis
factor (TNF)-alpha immunofluorescence staining. Cell-rich (c) and
cell-poor (d) intraluminal thrombus, with TNF-alpha expression of
the platelets and inflammatory cells (red color). Autofluorescence of
the endothelium (green arrow) (Color figure online)
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dilated arteries (Fig. 6). Additionally, arterial wall expo-
sure to paclitaxel inhibited fibrin deposition in the tunica
intima and media in the femoral arteries (Fig. 8), and in
the intima in the iliac arteries (Fig. 9).
3.3 Physiological response of the peripheral arteries
to balloon dilation
Enhanced endothelin-induced vasoconstriction in the
FreewayTM-treated peripheral arteries was more pro-
nounced in the femoral arteries than in the iliac arteries,
and showed rapid normalization at 3 days post-intervention
(Figs. 8, 9). The endothelium-dependent vasodilator reac-
tion was profoundly impaired during the first 3 days in the
femoral vessels but not in the iliac arteries, with no dif-
ference between the two balloon types. Endothelium-in-
dependent vasodilation did not change after balloon injury
in the femoral or iliac arteries (Figs. 8, 9).
4 Discussion
Our present study results provide novel data with transla-
tional value regarding the use of DCB in clinical practice.
We report that arterial dilation with the DCB FreewayTM
inhibited fibrin accumulation in the tunica intima and
media of the femoral arteries, leading to significantly less
constrictive remodeling of the injured vessel. However,
tissue uptake of the drug into the vessel wall after percu-
taneous intervention resulted in a predisposition to vessel
constriction in both the iliac and femoral arteries, as well as
impaired endothelium-dependent vasodilation of the
femoral arteries. Our present report also includes the
application of high-resolution OCT imaging for in vivo
display of peripheral vascular injury following the use of
an intravascular device, which demonstrated non-flow-
limiting dissection and thrombus formation with an
inflammatory reaction. Finally, we report the pathophysi-
ological differences between femoral and iliac arteries in
Fig. 4 OCT images of the femoral arteries before and after
percutaneous transluminal angioplasty (PTA) with FreewayTM (upper
panel) and plain balloon (bottom panel) and at follow-up (FUP).
a Pre-PTA: Image taken before percutaneous transluminal angio-
plasty (Pre-PTA) of the native femoral artery. b Post-PTA: Image
taken after balloon overstretch injury of femoral arteries, showing
white platelet-rich thrombi (blue arrow) at the site of intimal rupture
and intraluminally. Small attaching white thrombi (white arrow).
c Post-PTA (95 magnification) of a white intraluminal thrombus
(blue arrow) partially attaching to the vessel wall with an irregular
structure and shadowing (upper panel). The bottom panel shows
severe rupture of the intima and media (white arrow) with attaching
white thrombi. d 32 ± 2 days FUP: Medium- and high-grade
obstruction of the femoral arteries at 32 ± 2 days after balloon
overstretch injury. Shrinkage of the artery suggests severe constrictive
remodeling after plain balloon dilation (Color figure online)
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response to intravascular intervention using either the plain
balloon or DCB (Table 9).
4.1 Tissue and plasma drug levels after balloon
catheter-derived delivery: comparison with data
from the literature
Our present results showed that use of the FreewayTM DCB
led to paclitaxel accumulation in both the femoral and iliac
arteries, and the longitudinal distribution of this drug both
proximal and distal to the balloon dilation site. Yazdani
et al. previously reported much lower paclitaxel levels in
the arteria femoralis tissue of healthy domestic swine fol-
lowing their use of the Lutonix drug-coated balloon (Lu-
tonix Inc., New Hope, MN). However, in their study, the
femoral arteries were dilated without overstretch injury for
an inflation time of only 30 s [34]. In another study,
Buszmann et al. measured paclitaxel levels at 1 h after 30-s
dilation with the Cotavance DCB (MEDRAD Interven-
tional, Indianola, PA) in hypercholesterolemic domestic
pigs with in-stent restenosis of the peripheral arteries, and
reported paclitaxel tissue uptake of\50 ng/mg tissue [17].
Comparatively, our present study showed paclitaxel uptake
of 143 ± 60 and 460 ± 214 ng/mg femoral artery tissue at
1 h after balloon dilation with a 1- or 2-min inflation time,
respectively. Granada et al. [16] reported that histology, but
not quantitative angiography, is sufficiently sensitive to
determine the effect of a zotarolimus-coated balloon for
restenosis prevention. Like in our study, Kolachalama et al.
demonstrated that the tissue drug level of zotarolimus in
peripheral arteries was dependent on the balloon inflation
time [35].
In contrast with previously published peripheral DCB
studies, in our present study, we separately analyzed the
iliac and femoral arteries because these arteries differ in
structure and in their physiological responses to injury (as
shown in our study). We also applied optical imaging to
examine the morphological effects of balloon inflation in
the femoro-iliac arteries. OCT images of peripheral arteries
revealed severe post-dilation vessel injury, including
Fig. 5 OCT images of the iliac arteries pre- and post-percutaneous
transluminal angioplasty (PTA) and at follow-up (FUP). a Pre-PTA:
OCT image of a native iliac artery showing a blurred contour away
from the imaging probe, highlighting the difficulty of correctly
imaging large arteries. b Post-PTA: Post-balloon overstretch injury of
iliac arteries with large dissections (yellow arrows) and platelet-rich
white thrombi, both parietal and intraluminal (blue arrows). c Post-
PTA (95 magnification) of vessel wall dissection (yellow arrow) and
white intraluminal thrombus (blue arrow) partially attached to the
vessel wall with irregular structure and shadowing. d 32 ± 2 days
FUP: Partial medium-grade obstruction of the iliac arteries
32 ± 2 days after balloon overstretch injury. Artery shrinkage
suggests constrictive remodeling of the iliac vessels due to neointima
development, but to a lesser extent than in the femoral arteries (Color
figure online)
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dissections and luminal thrombi, and proved to be more
sensitive than angiography for the assessing lumen mor-
phology and dimensions, similar to histology.
It appears that a long presence and high concentration of
the drug in the arterial wall are crucial for inhibition of
neointimal proliferation and restenosis [36, 37]. In our
study, the paclitaxel tissue level was maintained over
9 days—beyond occurrence of the initial thrombotic and
inflammatory processes following vessel trauma from
endovascular interventions, and beyond the smooth muscle
cell migration and proliferation from the media and
adventitia. Longer presence of an antiproliferative drug—
especially one with a narrow therapeutic window, like
paclitaxel—could result in vascular toxicity, including
ectasia of the treated vessels [21]. Our present results
showed that a 1-min balloon inflation time in peripheral
arteries resulted in an artery tissue paclitaxel level similar
to that previously observed in coronary arteries [31, 32].
Due to the potential for untoward cardiac effects from
prolonged ischemia, a longer balloon inflation time is not
desirable in coronary arteries. Paclitaxel is released into
systemic circulation immediately after balloon inflation.
Fig. 6 Pharmacokinetic and histologic studies of the femoral arteries.
a Arteria femoralis tissue paclitaxel concentrations at different
follow-up times after a 1- or 2-min balloon inflation time. b Cross-
sections of porcine femoral arteries at 32 ± 2 days after overstretch
dilation. Uneven distribution of neointimal hyperplasia (red arrow)
after dilation with the plain balloon, and a circumferential small
degree of neointima (black arrow) after dilation with the FreewayTM
(left two panels). Arterial Sects. (94 magnification) showing neoin-
timal hyperplasia following dilation with either the plain balloon or
FreewayTM (right two panels). Hematoxylin–eosin staining. c Invasion
of smooth muscle cells showing positive alpha actin staining of
femoral arteries into the intima layer (yellow arrow), with substan-
tially fewer cells in the intima in the FreewayTM group. d Fibrin
deposition in the intima (black arrow) with a disintegrated internal
elastic lamina structure and no clear intersection between intimal
hyperplasia and tunica media after plain balloon overstretch injury
(left). In contrast, after FreewayTM dilation, thin neointimal hyper-
plasia was observed (blue arrow) (right). Picrosirius red staining, 98
magnification (Color figure online)
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Table 1 Quantitative
angiographic parameter of the
femoral arteries 32 ± 2 days
follow-up (FUP)




Lumen diameter pre-dilation (mm) 5.1 ± 0.3 5.2 ± 0.5
Lumen diameter post-dilation (mm) 6.6 ± 0.6 6.7 ± 0.6
Balloon/artery ratio 1.31 ± 0.08 1.29 ± 0.11
Lumen diameter at FUP (mm) 4.6 ± 0.7 5.2 ± 0.6
Vessel diameter at FUP (mm) 6.2 ± 0.6 6.3 ± 0.7
%Diameter stenosis at FUP (%) 25.8 ± 10.7 17.6 ± 12.2*
* P\ 0.05 between plain balloon and FreewayTM
Table 2 Quantitative
angiographic parameters of the
iliac arteries 32 ± 2 days
follow-up (FUP)




Lumen diameter pre-dilation (mm) 7.4 ± 0.6 7.5 ± 0.6
Lumen diameter post-dilation (mm) 9.7 ± 0.6 9.7 ± 0.6
Balloon/artery ratio 1.31 ± 0.10 1.31 ± 0.08
Lumen diameter at FUP (mm) 7.0 ± 0.5 7.2 ± 0.6
Vessel diameter at FUP (mm) 8.8 ± 0.8 8.7 ± 0.6
%Diameter stenosis at FUP (%) 20.5 ± 4.3? 17.2 ± 4.2
? P\ 0.1
Fig. 7 Pharmacokinetic and histologic studies. a Arteria iliaca tissue
paclitaxel concentration at different follow-up times after a 1- or
2-min balloon inflation time. b Cross-sections of porcine iliac arteries
at 32 ± 2 days after overstretch dilation, showing uneven distribution
of neointimal hyperplasia (red arrow) after dilation with a plain
balloon, and a circumferential small degree of neointima (black
arrow) after FreewayTM dilation (left two panels). Arterial Sects. (94
magnification) with neointimal hyperplasia after dilation with either
plain balloon or FreewayTM (right two panels). Focal neointimal
hyperplasia at the site of rupture of the internal elastic membrane,
with inflammatory cells in the media and adventitia (red arrow).
Minimal neointimal hyperplasia in arteries dilated with FreewayTM
(black arrow). Hematoxylin–eosin staining (Color figure online)
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The use of a 2-min balloon inflation time led to a gradual
decrease in the plasma drug level, corresponding to the
plasma paclitaxel clearance half-life [38]. Dose-finding
clinical investigations show that a plasma concentration
below 6.3 lmol/L (5400 ng/mL; well above the 15 ng/mL
maximal level in our study) is not associated with any
systemic toxicity [39, 40].
4.2 Vascular remodeling study
Paradoxical arterial (or constrictive) remodeling was first
described in femoral arteries by Pasterkamp et al. [41]. Our
present experiments revealed that paclitaxel accumulation
in the femoral arterial wall inhibited fibrin deposition in the
intimal and medial layers. Paclitaxel did not substantially
influence the amount of fibrous collagen in the tunica
media of the iliac arteries, but it did reduce fibrin deposi-
tion in the intima. Thus, the higher post-intervention lumen
area may be explained not only by inhibition of smooth
muscle cell migration into the intima, but also by preven-
tion of constrictive remodeling. While tissue drug levels
are published for other DCB systems, such vessel remod-
eling and pathophysiological studies have not yet been
performed for other DCBs.
Table 3 OCT parameters of the
femoral arteries at baseline (pre-
dilation), and at 32 ± 2 days
follow-up (n = 10 arteries of 5
animals)
Femoral arteries Plain balloon FreewayTM balloon
Baseline
Minimal lumen diameter (mm) 5.4 ± 0.3 5.4 ± 0.7
Vessel diameter (mm) 5.6 ± 0.4 5.6 ± 0.7
Minimal lumen area (mm2) 21.3 ± 3.2 20.1 ± 5.8
IEM area (mm2) 22 ± 3.3 21.1 ± 5.9
Follow-up
Minimal lumen diameter (mm) 3.1 ± 0.3 4.8 ± 0.5*
Vessel diameter (mm) 5.0 ± 1.2 5.8 ± 0.7
Minimal lumen area (mm2) 9.7 ± 1.5 17.8 ± 3.9*
Intima area (mm2) 7.3 ± 1.7 4.3 ± 2.4*
IEM area (mm2) 17.0 ± 3.1 22.1 ± 5.5
Percent area stenosis (%) 42.8 ± 3.1 18.7 ± 10.1*
IEM area of reference segment (mm2) 21.3 ± 1.9 21.8 ± 5.4
Remodeling index 0.80 ± 0.15 1.02 ± 0.03*
IEM internal elastic membrane
* P\ 0.05 between plain balloon and FreewayTM
Table 4 OCT parameters of the
iliac arteries at baseline (pre-
dilation), and at 32 ± 2 days
follow-up (n = 10 arteries of 5
animals)
Iliac arteries Plain balloon FreewayTM balloon
Baseline
Minimal lumen diameter (mm) 5.9 ± 0.9 5.9 ± 0.5
Vessel diameter (mm) 6.0 ± 0.8 6.1 ± 0.4
Minimal lumen area (mm2) 24.0 ± 4.9 23.8 ± 6.2
IEM area (mm2) 24.8 ± 4.6 24.6 ± 6.3
Follow-up
Minimal lumen diameter (mm) 5.2 ± 0.9 5.5 ± 0.9
Vessel diameter (mm) 6.2 ± 1.0 6.3 ± 0.5
Minimal lumen area (mm2) 18.5 ± 6.8 22.0 ± 7.3
Intima area (mm2) 8.2 ± 2.1 3.5 ± 1.6*
IEM area (mm2) 26.6 ± 6.0 25.5 ± 6.3
Percent area stenosis (%) 32.4 ± 13.4 14.9 ± 8.6*
IEM area of reference segment (mm2) 26.3 ± 2.1 25.5 ± 6.0
Remodeling index 1.01 ± 0.18 1.00 ± 0.03
IEM internal elastic membrane
* P\ 0.05 between plain balloon and FreewayTM
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4.3 Pathophysiological study
Our physiological investigation revealed that tissue drug level
was clearly associated with increased vasoconstrictor tone of
the affected vessel. This association was more pronounced in
the femoral arteries than in the iliac vessels during the first
days following overstretch injury. Dilation with the DCB led
to increased vasoconstrictive response in both the iliac and
femoral arteries, and notably in vessels with injury scores
similar to those of arteries dilatedwith the plain balloon. Thus,
the overstretch injury (denudation) of the arteries was not the
only cause of this pathological reaction.
Vascular procedures induce a reflexive, mechanically
induced vasospasm. In contrast to the coronary arteries
[29], the intact control peripheral vessels showed much
lower endothelium-dependent vasodilator capacity. Nota-
bly, endothelium-independent (muscular layer) vasodila-
tion was unaffected by the balloon overstretch injury, likely
due to the high fibrous collagen tissue content. The results
of our previous physiological studies in coronary arteries
[29] together with our current findings in peripheral ves-
sels, appear to indicate that the peripheral arteries are much
less reactive with regards to contraction and to endothe-
lium-dependent and -independent vasodilation. This fact
may be particularly important if coronary devices are tested
in rabbit iliac arteries.
4.4 Practical application and translational nature
of the study
The FreewayTM DCB is commercially available in Europe
and in several non-USA countries for human peripheral
artery interventions. However, animal studies of this device
still provide a unique opportunity to examine the reaction
of the host tissue; to investigate tissue pathology and
inflammation; to study drug retention, delivery, kinetics,
and toxicology; to assess systemic drug disposition or other
harmful effects related to the application of drugs and/or a
foreign body; and to further explore their mechanisms of
action. These data acquired from animal research can
directly lead to improvements of technological concepts
and to refinements of intravascular devices. In contrast,
human trials typically focus on the safety and efficacy of an
Table 5 Histopathological parameters of femoral arteries 32 ± 2 days
after balloon dilation with FreewayTM or plain balloon




Inflammation score 0.30 ± 0.22 0.32 ± 0.13
Hemorrhage 0 0
Necrosis 0 0
Medial injury 0.89 ± 0.11 0.93 ± 0.25
Endothelialization complete 100 % 100 %
Injury score 0.92 ± 0.64 0.90 ± 0.67
Calcification 0 0
No significant differences between the groups
Table 6 Histopathological parameters of the iliac arteries 32 ± 2 days
after balloon dilation with FreewayTM or plain balloon




Inflammation score 0.42 ± 0.17 0.45 ± 0.36
Hemorrhage 0 0
Necrosis 0 0
Medial injury 0.86 ± 0.22 0.79 ± 0.13
Endothelialization complete 100 % 95 ± 5 %
Injury score 1.0 ± 0.68 1.1 ± 0.83
Calcification 0 0
No significant differences between the groups
Table 7 Histomorphometric
parameters of the femoral
arteries 32 ± 2 days after
balloon dilation with either
plain balloon or FreewayTM
drug-coated balloon




Lumen area (mm2) 8.1 ± 1.7 10.2 ± 1.1*
Neointimal area (mm2) 3.7 ± 1.8 0.9 ± 0.1*
IEL area (mm2) 11.7 ± 2.2 11.1 ± 1.0
Media area (mm2) 6.6 ± 4.5 10.2 ± 2.8
EEL area (mm2) 18.3 ± 2.6 21.3 ± 2.1
%Area stenosis (%) 30.5 ± 14.2 8.3 ± 1.8*
Maximal neointimal thickness (mm) 2.9 ± 0.7 0.67 ± 0.32*
EEL area of the reference segment (mm2) 21.8 ± 2.6 21.5 ± 1.8
Remodeling index 0.84 ± 0.04 1.01 ± 0.07*
IEL internal elastic lamina, EEL external elastic lamina
* P\ 0.05 between plain balloon and FreewayTM
J Mater Sci: Mater Med (2016) 27:131 Page 11 of 15 131
123
interventional therapy, without attaining new information
regarding the underlying biology.
Accordingly, in our present animal model of the use of
peripheral intravascular DCB, we demonstrated that the drug
coating on an intravascular balloon surface did not cause
delayed re-endothelialization in peripheral arteries. Thus, in
contrast with drug-coated stents, the use of DCB could reduce
the duration of dual antiplatelet therapy [36], which is of
clinical interest. In cases of non-flow-limiting dissection, the
use of a DCB is apparently sufficient to prevent restenosis
without provisional stenting in peripheral arteries, thus
avoiding stent fractures or foreign body reactions. Moreover,
the use of DCBs for peripheral artery dilation prevents unfa-
vorable constrictive remodeling, thereby inhibiting disease
Table 8 Histomorphometric
parameters of the iliac arteries
32 ± 2 days after balloon
dilation with either plain
balloon or FreewayTM drug-
coated balloon




Lumen area (mm2) 10.3 ± 1.0 12.2 ± 1.5*
Neointimal area (mm2) 4.1 ± 0.7 2.3 ± 0.9*
IEL area (mm2) 14.4 ± 0.4 14.6 ± 1.2
Media area (mm2) 8.7 ± 2.3 9.8 ± 3.9
EEL area (mm2) 23.1 ± 1.9 24.3 ± 4.8
%Area stenosis (%) 28.3 ± 5.6 16.0 ± 6.3*
Maximal neointimal thickness (mm) 2.0 ± 0.2 0.94 ± 0.83*
EEL area of the reference segment (mm2) 23.8 ± 2.5 24.3 ± 4.8
Remodeling index 0.97 ± 0.03 1.01 ± 0.01
IEL internal elastic lamina, EEL external elastic lamina
* P\ 0.05 between plain balloon and FreewayTM in iliac arteries
Fig. 8 Time-dependent development of arterial tissue fibrosis (in-
tima) and fibrous collagen (media) after balloon dilation, and the
vasomotor response (vasoconstriction and vasodilation) of the
femoral arteries. a Time-dependent increase in arterial tissue fibro-
sis/collagen in the different femoral artery layers (intima, tunica
media, and adventitia) after dilation with the plain balloon or
FreewayTM paclitaxel-coated balloon. b Endothelin-induced contrac-
tion of the femoral artery (left). Susceptibility to contraction at 1 day
post-dilation with either type of balloon, followed by rapid normal-
ization. Profound injury of the endothelium-dependent vasodilatory
reaction, with no difference between the two balloon types (mid). No
change in endothelium-independent vasodilation (right). The gray
range represents the normal value ±1 standard deviation. *P\ 0.05
between balloon and control, ?P\ 0.05 between FreewayTM and
plain balloon. Number of arteries listed in Fig. 1
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progression. It is also notable that the impaired vasoreactivity
caused by drug deposition in the arterial wall requires more
aggressive post-intervention vasodilatory treatment.
4.5 Limitations
Percutaneous intervention of healthy porcine peripheral
arteries cannot mimic the peripheral intervention of
atherosclerotic human arteries, and is not entirely compa-
rable with the injury model of familial hypercholes-
terolemic swine [16]. It was recently proposed that deep
acute endothelium injury in hypercholesterolemic swine
could be used as an animal model for device assessment
[16]. However, the current guidelines for performing pre-
clinical tests in coronary and peripheral arteries do not
recommend the use of diseased porcine models [34].
Table 9 Currently available drug-coated balloons for peripheral artery disease




Aachen resonance holding (Luxembourg) Elutax Yes (2013) No PTX-Hydrogel 3.0
BARD (US) Lutonix Yes (2011) Yes (2014) PTX-polysorbate/Sorbitol 2.0
Bayer schering pharma AG (Germany) Cotavance Yes (2011) No PTX-Iopromide 3.0
Biotronik AG (Germany) Passeo-18 Lux Yes (2014) No PTX-BTHC 3.0
Cardionovum GmbH (Germany) Legflow Yes (2011/12) No PTX-Shellac 3.0
Cook medical (US) Advance 18 PTX Yes (2011) No PTX 3.0
Covidien (US) Stellarex No No PTX 2.0
Eurocor GmbH (Germany) Freeway Yes (n/a) No PTX-Shellac 3.0
Medtronic vascular (Switzerland) In.pact admiral Yes (2009) Yes (2014) PTX-Urea 3.0
Boston scientific (US) Ranger Yes No PTX-BTHC 2.0
iVascular (Spain) Luminor Yes No PTX 3.0
Fig. 9 Time-dependent development of arterial tissue fibrosis/colla-
gen after balloon dilation, and vasomotor response (vasoconstriction
and dilation) of the iliac arteries. a Time-dependent increase in
arterial tissue fibrosis/collagen in the different iliac artery layers
(intima, tunica media, and adventitia) after dilation with a plain
balloon or FreewayTM paclitaxel-coated balloon. b Endothelin-in-
duced iliac artery contraction (left). Susceptibility to contraction at
1 day post-dilation with the FreewayTM drug-coated balloon, fol-
lowed by rapid normalization. Normal endothelium-dependent and
endothelium-independent vasodilatory reaction after use of either
balloon types. The gray range represents the normal value ±1
standard deviation. *P\ 0.05 between balloon and control,
?P\ 0.05 between FreewayTM and plain balloon. Number of arteries
listed in Fig. 1
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Nevertheless, in our present study, visible injury of the
peripheral arteries was confirmed by angiography and OCT
following gross overdilation. It should also be noted that
the pathophysiological response of the denuded artery [16]
influences the endothelial uptake of locally delivered drugs.
Further limitations of this study are described in the Sup-
plemental Material.
5 Conclusions
Our present results demonstrated the safety and efficacy of
the FreewayTM paclitaxel-coated balloon in a preclinical
model of overstretch injury in peripheral arteries. The
observed beneficial effects of the FreewayTM balloon may
be attributed to inhibition of smooth muscle cell migration
and neointimal hyperplasia development, as well as pre-
vention of fibrosis of the intima and media, resulting in less
constrictive vessel remodeling. We also showed that higher
arterial wall paclitaxel concentration was associated with
local vasoconstriction and impaired endothelium-depen-
dent vasodilation. Furthermore, our findings show that
although high-resolution OCT imaging is technically
challenging, it was useful for in vivo display of peripheral
vascular injury after intravascular device usage, demon-
strating non-flow-limiting dissection and thrombus forma-
tion with inflammatory reaction in peripheral arteries.
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